NPM1 and acute myeloid leukemia: Lastly, our large cohort allowed us to better analyze the impact of CPX‐351 in some AML subtypes which are usually underrepresented among s‐AML, such as NPM1 or FLT3‐ITD mutated patients or favorable risk patients.